Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag + Azacitidine in Intermediate/High-Risk MDS (SUPPORT)
NCT02158936Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in Thrombocytopenia comparing Eltrombopag + Azacitidine with Placebo + Azacitidine (2 arms). Primary endpoint: Proportion of Participants Who Were Platelet Transfusion Independent During Cycles 1-4. Started Jun 2014; status: terminated.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02158936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158936.